For the treatment of adults

with community-acquired

bacterial pneumonia

The Total
CABP Package

XENLETA: the first and only oral and IV pleuromutilin empiric antibiotic that acts against the pathogens that commonly cause CABP.1,2

Demonstrated monotherapy efficacy

XENLETA achieved early and effective clinical response against common CABP pathogens in as short as 5 total days of therapy.1

See the results

Convenient oral or IV dosing flexibility

Start patients with IV, then switch to oral—or start with oral.1

Get the details

A novel mechanism of action

A pleuromutilin with a low propensity for resistance—some isolates resistant to other treatments may be susceptible to XENLETA.1

See how it works

Discuss XENLETA in person

Request a visit from a sales representative to learn more about XENLETA. Your sales rep can also provide sample packs.

Request a rep/sample pack